4 result(s) displayed (1 - 4 of 4):

Astellas Pharma throws lifeline to Maxygen (from Corporate Dealmaker)

Biotechnology firm Maxygen Inc. (NASDAQ:MAXY) has gotten a life-saving assist from Astellas Pharma Inc. of Japan. The companies are forming a joint venture that will keep Maxygen operating in a brutal market for developmental stage biotechs with no marketable products and sky-high R&D costs.  As this Deal Pipeline timeline shows (subscription required),...

Posted on July 2, 2009 11:00 AM

Megamergers? Not for Japanese pharmas, analyst says (from Corporate Dealmaker)

Don't look for Japanese pharmas to participate in the megamergers now underway in the sector, a Japanese analyst quoted in a Reuters report says. Look instead for bolt-ons.So far this year, announced megapharma deals include Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of smaller U.S. rival Wyeth; Merck & Co. (NYSE:MRK)...

Posted on March 17, 2009 11:58 AM

CV Therapeutics rejects Astellas bid, may get better offer (from Corporate Dealmaker)

Once again, CV Therapeutics Inc. of Palo Alto, Calif., rejected a $16 per share ($1 billion) buyout offer from Tokyo's Astellas Pharma Inc.CVT agreed to reconsider the offer after Astellas made the bid public in late January (one day after Pfizer Inc. announced its $68 billion acquisition of Wyeth). CVT...

Posted on February 20, 2009 9:20 AM

Astellas Pharma offers $1B for CV Therapeutics (from Corporate Dealmaker)

Tokyo's Astellas Pharma Inc. took to the newswires and made another unsolicited bid to acquire CV Therapeutics Inc. of Palo Alto, Calif. The $16 per share ($1 billion) offer is Astellas' second attempt in three months at buying the heart drugmaker. Perhaps it feels the timing is better with Pfizer...

Posted on January 27, 2009 9:26 AM